⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796373 | 0.86 | CA1 (0.43) | — | |
| SCHEMBL171969 | 0.86 | — | — | |
| SCHEMBL13125935 | 0.83 | KMT2A (0.46) | — | |
| SCHEMBL10884969 | 0.77 | — | — | |
| SCHEMBL18151504 | 0.69 | — | — | |
| SCHEMBL1177125 | 0.67 | CRBN (0.43) | — | |
| SCHEMBL7825990 | 0.67 | CA1 (0.32) | — | |
| SCHEMBL1551749 | 0.67 | — | — | |
| SCHEMBL4598176 | 0.65 | — | — | |
| Bromide SCHEMBL3997504 | 0.64 | MAPT (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731610-A1 | TRADD INHIBITOR AND USE THEREOF | Nanjing Reju Therapeutics Co. Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024260316-A1 | TRADD INHIBITOR AND USE THEREOF | NANJING REJUTHERAPEUTICS, INC. (CN) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| US-9978956-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2018-05-22 | — | — | US | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-2007382-A1 | THIAZOLYLDIHYDROCYCLOPENTAPYRAZOLES FOR USE AS PI3-KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-7351867-B2 | Catalyst system for aerobic oxidation of primary and secondary alcohols | THE NUTRASWEET COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351867-B2 | Catalyst system for aerobic oxidation of primary and secondary alcohols | THE NUTRASWEET COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007115931-A1 | THIAZOLYLDIHYDROCYCLOPENTAPYRAZOLES FOR USE AS PI3-KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1802636-A1 | PI3 KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-04 | — | — | EP | disclosed |
| US-20070078284-A1 | Catalyst system for aerobic oxidation of primary and secondary alcohols | THE NUTRASWEET COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078284-A1 | Catalyst system for aerobic oxidation of primary and secondary alcohols | THE NUTRASWEET COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20060106013-A1 | PI3-kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006040279-A1 | PI3 KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |